SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
mds25218-sup-0001-suppfig1A.tif668KSupplementary Figure 1: (A) Development of locomotive AIMs in 6-OHDA-lesioned rats. Animals were switched from Group 1: pulsatile levodopa/carbidopa (7.85/carbidopa 12.5mg/kg i.p.) to continuous levodopa/carbidopa (0.8/0.2mg/h i.d. plus carbidopa 12.5mg/kg i.p.), Group 2: vehicle i.p. to i.d., Group 3: continuous levodopa/carbidopa (0.8/0.2mg/h i.d. plus carbidopa 12.5mg/kg i.p.) to pulsatile levodopa/carbidopa (7.85/carbidopa 12.5mg/kg i.p.) and Group 4: vehicle i.d. to i.p. Data are medians + or – interquartile range (n=7-10). # p<0.05 compared to day 0 (Phase 1; Kruskal-Wallis followed by Mann-Whitney test) * p < 0.05 compared to vehicle on each day (Kruskal-Wallis followed by Wilcoxon test) (B) Total locomotive AIMs scores for Group 1 and Group 3 in Phase I and Phase II. (n=7-10).
mds25218-sup-0002-suppfig1B.tif462KSupplementary Figure 1: (A) Development of locomotive AIMs in 6-OHDA-lesioned rats. Animals were switched from Group 1: pulsatile levodopa/carbidopa (7.85/carbidopa 12.5mg/kg i.p.) to continuous levodopa/carbidopa (0.8/0.2mg/h i.d. plus carbidopa 12.5mg/kg i.p.), Group 2: vehicle i.p. to i.d., Group 3: continuous levodopa/carbidopa (0.8/0.2mg/h i.d. plus carbidopa 12.5mg/kg i.p.) to pulsatile levodopa/carbidopa (7.85/carbidopa 12.5mg/kg i.p.) and Group 4: vehicle i.d. to i.p. Data are medians + or – interquartile range (n=7-10). # p<0.05 compared to day 0 (Phase 1; Kruskal-Wallis followed by Mann-Whitney test) * p < 0.05 compared to vehicle on each day (Kruskal-Wallis followed by Wilcoxon test) (B) Total locomotive AIMs scores for Group 1 and Group 3 in Phase I and Phase II. (n=7-10).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.